Key clinical point: Fremanezumab demonstrated early and sustained efficacy with an optimal safety profile in patients with high disability and high-frequency episodic migraine (HFEM) or chronic migraine (CM) with multiple preventive failures and diverse comorbidities.
Major finding: At 21-24 weeks, fremanezumab significantly reduced monthly migraine days in patients with HFEM (−6.9 ± 3.6; P < .001) and monthly headache days in patients with CM (−14.2 ± 7.6; P < .001) along with significant reductions in monthly analgesic medications and Numerical Rating Scale scores in both patients with HFEM and CM ( P < .001), with benefits sustaining throughout treatment period and adverse events being rare.
Study details: This multicenter, prospective real-life study included 148 patients with migraine (HFEM, n = 52; CM, n = 96) who were treated with fremanezumab for ≥24 weeks.
Disclosures: The study was partially supported by the Italian Ministry of Health Institutional Funding Ricerca Corrente San Raffaele Roma, Italy. Some authors declared receiving research support, travel grants, or honoraria for advisory board participation, speaking, or clinical investigation studies from various sources.
Source: Barbanti P et al for the FRIEND-Study Group. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: The multicenter, prospective, real-life FRIEND2 study. J Headache Pain. 2023;24:30 (Mar 23). Doi: 10.1186/s10194-023-01561-w